Colorectal Cancer Therapeutics Market in APAC 2015-2019

Colorectal Cancer Therapeutics Market in APAC 2015-2019

  • December 2015 •
  • 106 pages •
  • Report ID: 3506473 •
  • Format: PDF
About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- APAC
- China
- Japan


Key vendors
- Amgen
- Bayer
- Bristol-Myers Squibb
- Chugai Pharmaceuticals
- Merck
- Sanofi

Other prominent vendors
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- AVEO Oncology
- Bavarian Nordic
- Biothera
- Boehringer Ingelheim
- Boston Biomedical
- Cancer Prevention Pharmaceuticals
- Celator Pharmaceuticals
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- EpicentRx
- GlaxoSmithKline
- Hutchison Medipharma
- Immodulon Therapeutics
- Immunomedics
- MacroGenics
- Merrimack Pharmaceuticals
- MolMed
- Mologen
- Morphotek
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- PledPharma
- Precision Biologics
- PsiOxus Therapeutics
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva Pharmaceuticals
- ThromboGenics
- Xbiotech
- Yakult Honsha

Key market driver
- Increase in aging population
- For a full, detailed list, view our report

Key market challenge
- Unknown disease etiology
- For a full, detailed list, view our report

Key market trend
- Rise in public awareness
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.